Korro Bio is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, advancing genetic medicines via its OPERA RNA-editing platform. The approach uses the body's natural RNA-editing processes for precise, temporary single-base corrections, which expands options in genetic medicine and lowers the chance of lasting off-target effects compared with DNA-editing methods.
The lead candidate, KRRO-121, targets urea cycle disorders and hepatic encephalopathy, while KRRO-111 focuses on alpha-1 antitrypsin deficiency. I follow KRRO closely for its differentiated technology, progress in both rare and more common liver conditions, and the upcoming clinical and regulatory events that could shift its valuation.
Over the past 30 days, KRRO advanced approximately 32%, moving from a closing price near $9.29 to roughly $12.25. The path was uneven, with a strong surge late in October followed by some pullback in mid-November as early excitement around the earnings release eased.
The three-month picture shows more restraint. About three months ago the stock traded near $12.96, so KRRO is down approximately 5% for the full quarter even after the recent move. Volatility has been pronounced, with a low near $8.34 in mid-October and an intraday peak above $17 in early November. This pattern is typical for a clinical-stage biotech where pipeline news drives swings more than near-term sales.
Several concrete developments supported the gain. On November 5, Korro Bio released third-quarter 2026 results showing a net loss of approximately $17.5 million and an adjusted per-share loss of about $0.98, better than consensus estimates near $1.26. The company also began dosing healthy volunteers in the Phase 1/2 ANCHOR trial of KRRO-121 and received FDA rare pediatric disease designation for the program.
KRRO-111 delivered more than 95% SERPINA1 mRNA editing in preclinical work, underscoring platform strength. Cash, cash equivalents, and marketable securities stood at $124.8 million at quarter-end, supporting operations into the second half of 2028. Analyst notes added lift, with Oppenheimer at a $22 target, Citi at $21, and Piper Sandler at $30, all Buy-rated; RBC Capital held a $10 target and Neutral stance. A counterpoint arrived when Novo Nordisk notified Korro on November 3 that it would end the research collaboration and license agreement, effective February 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing three months, KRRO moved within a wide range as investors balanced pipeline progress against ongoing losses and cash use. A decline in September and early October pushed shares toward multi-month lows before positive clinical updates and supportive analyst commentary fueled a recovery into early November.
The broader story centers on moving Korro's lead assets from preclinical into clinical stages. First-in-human dosing for KRRO-121 and robust preclinical editing data for KRRO-111 represented an inflection that the market rewarded, even as the Novo Nordisk collaboration wind-down and lack of near-term revenue prevented the stock from holding its early-November peaks.
Clinical execution remains the primary catalyst. Continued enrollment and dosing in the Phase 1/2 ANCHOR trial of KRRO-121, with patient dosing in urea cycle disorders expected in the first half of 2027 and an interim readout in the second half of 2027, will be closely followed. Korro has also guided toward a regulatory submission for KRRO-111 in the first half of 2027.
Financial management and the cash runway stay important given persistent losses. Updates on the Novo Nordisk collaboration wind-down and remaining deferred revenue could affect quarterly results. Sector sentiment around genetic medicines, shifts in analyst targets, and competitive moves in RNA editing will also matter. As with any clinical-stage biotech, outcomes hinge on trial data.
When tracking names like KRRO, I often review automated strategies on Tickeron’s Trending AI Robots page. It surfaces top-performing bots from a broad universe, letting me compare approaches across timeframes and risk levels without sifting through every option. This adds a practical layer to traditional analysis and helps gauge how algorithmic systems are positioned around clinical-stage stocks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.596). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology